十七烷酰胺 | 25844-13-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 十七烷酰胺
• 英文名称: heptadecanamide
• 英文别名: heptadecanoic acid[2,6-diethyl-2,3,6-trimethyl-1-(1-phenyl-ethoxy)-piperidin-4-yl]-amide
• CAS: 25844-13-7
• 化学式: C₁₇H₃₅NO
• 分子量: 269.471
• InChiKey: REEPJBYQLCWOAR-UHFFFAOYSA-N

物化性质

• 沸点：
  406.1±13.0 °C(Predicted)
• 密度：
  0.869±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  19
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  十七烷酰胺 生成 N-trimethylsilylheptadecanamide
  参考文献：
  名称：

  ARAFAT, EL SAYED;TRIMBLE, JOANN;ANDERSEN, RICHARD N.;DASS, CHABIL;DESIDER+, PITTSBURGH CONF. AND EXPO. ANAL. CHEM. AND APPL. SPECTROSC., NEW YORK, N.+

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 氨 作用下， 生成 十七烷酰胺
  参考文献：
  名称：

  Le Sueur, Journal of the Chemical Society, 1904, vol. 85, p. 833

  摘要：

  DOI：

文献信息

• [EN] INSULIN DIMER-INCRETIN CONJUGATES<br/>[FR] CONJUGUÉS DIMÈRES D'INSULINE-INCRÉTINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2017189342A1

  公开（公告）日：2017-11-02

  Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.

  已披露将胰岛素二聚体与至少具有一种胰岛素增效活性的肽共轭化。
• Process for the preparation of benzotriazoles
  申请人：——

  公开号：US20040019220A1

  公开（公告）日：2004-01-29

  A process for the preparation of compounds of formula (I): wherein the general symbols are as defined in claim 1, which comprises reacting a compound of formula (V): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 18 are as defined in claim 1, and R 18 is especially nitro, chlorine or bromine, with an azide compound of formula (IX): wherein M and n are as defined in claim 1, especially with sodium azide.

  一种制备化合物的方法，其化学式为（I）：其中一般符号如权利要求书中所定义，包括将化合物的化学式为（V）：其中R1，R2，R3，R4，R5，R6，R7，R8，R9和R18如权利要求书中所定义，且R18特别是硝基、氯或溴，与化学式为（IX）的叠氮化合物发生反应：其中M和n如权利要求书中所定义，特别是与叠氮化钠反应。
• [EN] PCSK9 ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS ANTAGONISTES DU PCSK
  申请人：MERCK SHARP & DOHME

  公开号：WO2021127460A1

  公开（公告）日：2021-06-24

  Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof: (I) wherein A, A1, A2, R1, R2 and R3 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

  揭示了化合物的结构式（I），或其药用盐：（I）其中A，A1，A2，R1，R2和R3如本文所定义，这些化合物具有拮抗PCSK9的属性。还描述了包含结构式I的化合物或其盐的制药配方，以及治疗心血管疾病和与PCSK9活性相关的疾病的方法，例如动脉粥样硬化，高胆固醇血症，冠心病，代谢综合征，急性冠状综合征或相关心血管疾病和心脏代谢疾病的条件。
• NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF
  申请人：WAKUNAGA PHARMACEUTICAL CO., LTD.

  公开号：US20200062752A1

  公开（公告）日：2020-02-27

  It is intended to provide a novel compound having high antitumor activity and low toxicity to normal cells. The present invention provides a pyridone carboxylic acid derivative represented by the following formula (1) or a salt thereof wherein R 1 represents a hydrogen atom, a halogen atom or the like; R 2 represents a hydrogen atom, a halogen atom or the like; R 3 to R 6 each represent a hydrogen atom or the like; R 7 represents a hydrogen atom or the like; R 8 represents a hydrogen atom, a halogen atom, the following formula (a) (wherein R a1 and R a2 each represent a hydrogen atom, a hydroxy group, an optionally substituted lower alkyl group or the like) or the like, or R 7 and R 8 together represent —N—OR 10 (wherein R 10 represents a hydrogen atom, an optionally substituted lower alkyl group, or an aralkyl group), or R 7 and R 8 form an optionally substituted 4- to 6-membered saturated hetero ring together with the adjacent carbon atom, or the like; R 9 represents a hydrogen atom or the like; X represents a nitrogen atom or the like; and Y represents a nitrogen atom or the like.

  本发明旨在提供一种具有高抗肿瘤活性和低毒性对正常细胞的新型化合物。本发明提供一种由以下式(1)表示的吡啶酮羧酸衍生物或其盐，其中R1代表氢原子、卤素原子或类似物；R2代表氢原子、卤素原子或类似物；R3至R6各自代表氢原子或类似物；R7代表氢原子或类似物；R8代表氢原子、卤素原子、以下式(a)（其中Ra1和Ra2各自代表氢原子、羟基、可选择取代的低烷基基团或类似物）或类似物，或者R7和R8一起代表—N—OR10（其中R10代表氢原子、可选择取代的低烷基基团或芳基烷基基团），或者R7和R8与相邻碳原子一起形成可选择取代的4-至6元饱和杂环，或类似物；R9代表氢原子或类似物；X代表氮原子或类似物；Y代表氮原子或类似物。
• Novel bipyridine derivatives
  申请人：Kuwabara Hirokazu

  公开号：US20050085642A1

  公开（公告）日：2005-04-21

  The invention provides a bipyridine derivative useful as an intermediate for pharmaceutical products, agricultural chemicals, electrophotographic photosensitive materials, dyes and the like, which is a bipyridine derivative represented by the general formula (I) and a salt thereof: wherein R1 represents an alkyl group with 2 to 20 carbon atoms having a substituent, substituted or unsubstituted aminomethyl group, trifluoromethyl group, substituted or unsubstituted thiomethyl group, substituted or unsubstituted alkenyl group, substituted or unsubstituted alkoxy group, substituted or unsubstituted aryloxy group, substituted carbonyl group, substituted sulfonyl group, unsubstituted or monosubstituted carbamoyl group, unsubstituted or monosubstituted sulfamoyl group, substituted or unsubstituted thiol group, unsubstituted or monosubstituted amino group, substituted carbonylamino group, substituted or unsubstituted ureido group, nitro group, cyano group, formyl group or an equivalent thereof, iodine atom or fluorine atom.

  该发明提供了一种对制药产品、农药化学品、电子感光材料、染料等具有中间体作用的双吡啶衍生物，其为一种由通式（I）表示的双吡啶衍生物及其盐：其中R1代表具有取代基的2至20个碳原子的烷基基团，取代或未取代氨甲基基团，三氟甲基基团，取代或未取代硫甲基基团，取代或未取代烯基基团，取代或未取代烷氧基团，取代或未取代芳氧基团，取代羰基团，取代磺酰基团，未取代或单取代的氨甲酰基团，未取代或单取代的磺酰胺基团，取代或未取代硫醇基团，未取代或单取代的氨基团，取代羰基氨基团，取代或未取代脲基团，硝基基团，氰基团，甲酰基团或其等效物，碘原子或氟原子。